Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanjivani Paranteral Ltd shared its Q4 and FY25 investor presentation with BSE. FY25 revenue from operations rose 28.8% YoY to ₹701 Mn, with PAT up 31.4% to ₹81 Mn and EBITDA up 32.1% to ₹115.7 Mn. Q4 FY25 was even stronger, with revenue up 41.3% YoY to ₹181.8 Mn and PAT up 74.4% to ₹21.9 Mn, driven mainly by injectables (69.3% of Q4 revenue). Exports dominate at 81.5% of FY25 revenue, with Latin America and Middle East/Africa as key markets. The company operates 4 manufacturing plants across India and Czech Republic and outlined qualitative growth drivers including product portfolio expansion, new geographies, therapeutic diversification, and strategic partnerships.
Strong YoY growth in revenue and profitability, with consistent margin profile, signals healthy operational momentum. However, sharp rise in receivables days (from 32 to 87) and long-term borrowings (from ₹9.7 Mn to ₹52.9 Mn) are points investors should watch closely.